Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2011

01-03-2011 | Original Article

Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy

Authors: Claudio Rapezzi, Candida Cristina Quarta, Pier Luigi Guidalotti, Simone Longhi, Cinzia Pettinato, Ornella Leone, Alessandra Ferlini, Fabrizio Salvi, Pamela Gallo, Christian Gagliardi, Angelo Branzi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2011

Login to get access

Abstract

Purpose

We previously reported in a small series of patients that 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy tested positive in transthyretin-related (TTR) (both mutant and wild-type) but not in primary (AL) amyloidotic cardiomyopathy (AC). We extended our study to a larger cohort of patients with AC.

Methods

We evaluated (1) 45 patients with TTR-related AC (28 mutant and 17 wild-type), (2) 34 with AL-related AC and (3) 15 non-affected controls. Myocardial uptake of 99mTc-DPD (740 MBq i.v.) was semiquantitatively and visually assessed at 5 min and at 3 h.

Results

Heart retention (HR) and heart to whole-body retention ratio (H/WB) of late 99mTc-DPD uptake were higher among TTR-related AC (HR 7.8%; H/WB 10.4) compared with both unaffected controls (HR 3.5%; H/WB 5.7; p < 0.0001) and AL-related AC (HR 4.0%; H/WB 6.1; p < 0.0001). For the diagnosis of TTR-related AC, positive and negative predictive accuracy of visual scoring of cardiac retention were: 80 and 100% (visual score ≥1); 88 and 100% (visual score ≥2); and 100 and 68% (visual score = 3). At adjusted linear regression analysis, TTR aetiology turned out to be the only positive predictor of increasing 99mTc-DPD uptake in terms of both HR [β 2.5, 95% confidence interval (CI) 1.5–3.5; p < 0.0001] and H/WB (β 3.5, 95% CI 2.1–4.9; p < 0.0001).

Conclusion

While 99mTc-DPD scintigraphy was confirmed to be useful for differentiating TTR from AL-related AC, diagnostic accuracy was lower than previously reported due to a mild degree of tracer uptake in about one third of AL patients. 99mTc-DPD scintigraphy can provide an accurate differential diagnosis in cases of absent or intense uptake evaluated by visual score.
Literature
2.
go back to reference Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;166:1805–13.CrossRefPubMed Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;166:1805–13.CrossRefPubMed
3.
go back to reference Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 1999;74:490–4.CrossRefPubMed Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 1999;74:490–4.CrossRefPubMed
4.
go back to reference Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411–5.CrossRefPubMed Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411–5.CrossRefPubMed
5.
go back to reference Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101–10.CrossRefPubMed Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101–10.CrossRefPubMed
6.
go back to reference Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108–14.PubMed Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108–14.PubMed
7.
go back to reference Benson MD, Breall J, Cummings OW, Liepnieks JJ. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 2009;16:9–14.CrossRefPubMed Benson MD, Breall J, Cummings OW, Liepnieks JJ. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 2009;16:9–14.CrossRefPubMed
8.
go back to reference Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–84.CrossRefPubMed Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–84.CrossRefPubMed
9.
go back to reference Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–28.CrossRefPubMed Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–28.CrossRefPubMed
10.
go back to reference Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12.CrossRefPubMed Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12.CrossRefPubMed
11.
go back to reference Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346(23):1786–91.CrossRefPubMed Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346(23):1786–91.CrossRefPubMed
12.
go back to reference Ferlini A, Fini S, Salvi F, Patrosso MC, Vezzoni P, Forabosco A. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J 1992;6:2864–6.PubMed Ferlini A, Fini S, Salvi F, Patrosso MC, Vezzoni P, Forabosco A. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J 1992;6:2864–6.PubMed
13.
go back to reference Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101:395–400.CrossRefPubMed Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101:395–400.CrossRefPubMed
14.
go back to reference Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006;136:715–20.PubMed Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006;136:715–20.PubMed
15.
go back to reference Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425–9.CrossRefPubMed Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425–9.CrossRefPubMed
16.
go back to reference Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702–14.CrossRefPubMed Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702–14.CrossRefPubMed
17.
go back to reference Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007;48:865–72.CrossRefPubMed Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007;48:865–72.CrossRefPubMed
18.
go back to reference Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508–13.CrossRefPubMed Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508–13.CrossRefPubMed
19.
go back to reference Hawkins P. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649–55.CrossRefPubMed Hawkins P. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649–55.CrossRefPubMed
20.
go back to reference Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22:1393–401.CrossRefPubMed Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22:1393–401.CrossRefPubMed
21.
go back to reference Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon FW, et al. Preliminary experience of 99mTc-aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79:494–500.CrossRefPubMed Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon FW, et al. Preliminary experience of 99mTc-aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79:494–500.CrossRefPubMed
22.
go back to reference Schaadt BK, Hendel HW, Gimsing P, Jønsson V, Pedersen H, Hesse B. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44:177–83.PubMed Schaadt BK, Hendel HW, Gimsing P, Jønsson V, Pedersen H, Hesse B. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44:177–83.PubMed
23.
go back to reference Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122–9.CrossRefPubMed Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122–9.CrossRefPubMed
24.
go back to reference Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29:168–74.CrossRefPubMed Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29:168–74.CrossRefPubMed
25.
go back to reference Leinonen H, Tötterman KJ, Korppi-Tommola T, Korhola O. Negative myocardial technetium-99m pyrophosphate scintigraphy in amyloid heart disease associated with type AA systemic amyloidosis. Am J Cardiol 1984;53:380–1.CrossRefPubMed Leinonen H, Tötterman KJ, Korppi-Tommola T, Korhola O. Negative myocardial technetium-99m pyrophosphate scintigraphy in amyloid heart disease associated with type AA systemic amyloidosis. Am J Cardiol 1984;53:380–1.CrossRefPubMed
26.
go back to reference Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 1984;52:321–6.CrossRefPubMed Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 1984;52:321–6.CrossRefPubMed
27.
go back to reference Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 1993;34:1612–5.PubMed Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 1993;34:1612–5.PubMed
28.
go back to reference Ak I, Vardareli E, Erdinĉ O, Kasapoğlu E, Ata N. Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin Nucl Med 2000;25:826–7.CrossRefPubMed Ak I, Vardareli E, Erdinĉ O, Kasapoğlu E, Ata N. Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin Nucl Med 2000;25:826–7.CrossRefPubMed
29.
go back to reference Puille M, Altland K, Linke RP, Steen-Müller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376–9.CrossRefPubMed Puille M, Altland K, Linke RP, Steen-Müller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376–9.CrossRefPubMed
30.
go back to reference Kulhanek J, Movahed A. Uptake of technetium 99m HDP in cardiac amyloidosis. Int J Cardiovasc Imaging 2003;19:225–7.CrossRefPubMed Kulhanek J, Movahed A. Uptake of technetium 99m HDP in cardiac amyloidosis. Int J Cardiovasc Imaging 2003;19:225–7.CrossRefPubMed
31.
go back to reference Falk RH, Lee VW, Rubinow A, Hood Jr WB, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983;51:826–30.CrossRefPubMed Falk RH, Lee VW, Rubinow A, Hood Jr WB, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983;51:826–30.CrossRefPubMed
32.
go back to reference Willerson JT, Parkey RW, Bowe TJ, Lewis SE, Corbett J, Buja LM. Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy. Semin Nucl Med 1980;10:54–69.CrossRefPubMed Willerson JT, Parkey RW, Bowe TJ, Lewis SE, Corbett J, Buja LM. Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy. Semin Nucl Med 1980;10:54–69.CrossRefPubMed
33.
go back to reference Yood RA, Skinner M, Cohen AS, Lee VW. Soft tissue uptake of bone seeking radionuclide in amyloidosis. J Rheumatol 1981;8:760–6.PubMed Yood RA, Skinner M, Cohen AS, Lee VW. Soft tissue uptake of bone seeking radionuclide in amyloidosis. J Rheumatol 1981;8:760–6.PubMed
Metadata
Title
Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy
Authors
Claudio Rapezzi
Candida Cristina Quarta
Pier Luigi Guidalotti
Simone Longhi
Cinzia Pettinato
Ornella Leone
Alessandra Ferlini
Fabrizio Salvi
Pamela Gallo
Christian Gagliardi
Angelo Branzi
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1642-7

Other articles of this Issue 3/2011

European Journal of Nuclear Medicine and Molecular Imaging 3/2011 Go to the issue